Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

BACKGROUND: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug interactions (DDIs) that could affect the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Csonka, Dénes, Bruderer, Shirin, Schultz, Armin, Soergel, Marianne, Stepanova, Radka, Sabattini, Giancarlo, Perez-Ruixo, Juan Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842351/
https://www.ncbi.nlm.nih.gov/pubmed/31552642
http://dx.doi.org/10.1007/s40261-019-00857-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842351/
https://www.ncbi.nlm.nih.gov/pubmed/31552642
http://dx.doi.org/10.1007/s40261-019-00857-7

Ejemplares similares